NeuroVive completes a directed share issue of SEK 65 million for continued expansion

NeuroVive Pharmaceutical AB (publ) (”NeuroVive” or the “Company”, OMX:NVP) today
announces that the Company has completed a directed share issue of 1.3 million
new shares, which brings SEK 65 million to the Company before transaction costs.

The new share issue, which was approved by the board of the Company on 19
February 2015 with authorization from the Annual General Meeting on 9 May 2014,
includes 1,300,000 new shares and has been directed to a limited group of
Swedish and international institutional qualified investors at a price of SEK 50
per share through a private placement procedure.

The proceeds from the directed share issue strengthens NeuroVive’s working
capital and enables value-creating investments, including preparations for the
upcoming commercialization of CicloMulsion® in Europe as well as continued
development of NeuroSTAT® and other product candidates.

“We are very pleased with the interest in the new share issue and welcome our
new shareholders. The new issue strengthens NeuroVive’s financial position and
enables further investments in our project portfolio where we foremost look
forward to phase III-data regarding CicloMulsion® during the third quarter of
2015. The share issue enables us to continue our transformation from a
development company to a profitable pharmaceutical company”, comments Mikael
Brönnegård, CEO of NeuroVive.

The reasons for the deviation from the shareholders’ pre-emptive rights are that
the board of the Company deems it beneficial for the Company and the
shareholders to expand the Company´s institutional and international shareholder
base but also to capitalize on the opportunity to raise new capital to the
Company at attractive terms.

The subscription price has been set through a customary bookbuilding process.
The subscription price entails a discount of approximately 14.4 percent in
relation to the average closing price for the last 30 trading days.

The new share issue in NeuroVive increases the number of shares by 1,300,000
shares from 27,788,093 shares to 29,088,093 shares in total and increases the
share capital by SEK 65,000.00 from SEK 1,389,404.65 to SEK 1,454,404.65 in
total. The new share issue entails a dilution of approximately 4.5 percent.

Baulos Capital Belgium SA, one of the largest shareholders of the Company, has
in connection with the new issue lent 1,300,000 shares in NeuroVive to ABG
Sundal Collier to enable delivery of subscribed shares to investors. These
shares will be returned to the lender after registration of the share issue with
the Swedish Companies Registration Office (Sw. Bolagsverket).

Advisors
ABG Sundal Collier acted as Joint Lead Manager and Sole Bookrunner, HDR Partners
acted as Joint Lead Manager, and Advokatfirman Lindahl acted as legal advisor to
NeuroVive in connection with the new share issue.

About NeuroVive Pharmaceutical
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is
developing a portfolio of products to treat acute cardiovascular and
neurological conditions through mitochondrial protection. These medical
conditions are characterized by a pressing medical need and have no approved
pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion®
(heart attack) and NeuroSTAT® (traumatic brain injury) are currently being
evaluated in phase III and phase II studies, respectively. NeuroVive’s research
programs also include products for the treatment of brain cell injury in stroke
patients, and drug candidates for cellular protection and treating mitochondria
-related energy regulation diseases. NeuroVive’s shares are listed on Nasdaq
Stockholm, Sweden.

For Investor Relations and media questions, please contact:
Ingmar Rentzhog, Laika Consulting, Tel: +46 (0)46 275 62 21 or ir@neurovive.se
It is also possible to arrange an interview with NeuroVive’s CEO Mikael
Brönnegård or COO Jan Nilsson at the above contact.

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
info@neurovive.se, www.neurovive.se

NeuroVive Pharmaceutical AB (publ) is required to publish the information in
this news release under The Swedish Securities Market Act. The information was
submitted for publication on 20 February 2015, at 8.30 a.m. CET.

Important information
Publication or distribution of this press release in certain jurisdictions may
be subject to restrictions according to law and the people in jurisdictions
where this press release has been made public or distributed should inform
themselves and follow such local restrictions. This press release does not
contain and does not constitute or form part of an invitation to acquire or
subscribe or a solicitation of any offer to buy or subscribe for shares,
subscription rights or other securities in NeuroVive Pharmaceutical AB (publ).

This press release may not be published or distributed, directly or indirectly,
in or into the U.S., Canada, Japan, Hong Kong, New Zeeland, South Africa,
Australia or in any other jurisdiction where such distribution would be
prohibited by applicable law. The information in this press release may not be
redistributed, reproduced or passed on in ways that conflict with applicable
restrictions. Failure to comply with these restrictions may constitute a
violation of the United States Securities Act of 1933 (“Securities Act”) or
applicable laws of other jurisdictions.